BIOTRICITY INC
For the period ended Mar 31, 2024. Filed Jun 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 27, 2024
BTCY$0.06+5.4%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
| Year Ended March 31, 2024 | Year Ended March 31, 2023 | |
|---|---|---|
| $ | $ | |
| REVENUE | 12,063,345 | 9,639,057 |
| Cost of Revenue | 3,707,064 | 4,197,024 |
| GROSS PROFIT | 8,356,281 | 5,442,033 |
| EXPENSES | ||
| Selling, general and administrative expenses | 14,612,724 | 17,621,865 |
| Research and development expenses | 2,571,826 | 3,229,879 |
| TOTAL OPERATING EXPENSES | 17,184,550 | 20,851,744 |
| LOSS FROM OPERATIONS | (8,828,269) | (15,409,711) |
| Other income/(expense) [Notes 3, 5] | (102,607) | (110,822) |
| Interest expense [Notes 5, 6, 7] | (3,018,803) | (1,839,159) |
| Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 5] | 18,539 | (71,119) |
| Accretion and amortization expenses [Notes 5, 6] | (2,172,920) | (743,459) |
| Change in fair value of derivative liabilities [Note 8] | 9,777 | (483,873) |
| NET LOSS BEFORE INCOME TAXES | (14,094,283) | (18,658,143) |
| Income taxes [Note 10] | — | — |
| NET LOSS BEFORE DIVIDENDS | (14,094,283) | (18,658,143) |
| Preferred Stock Dividends | (834,677) | (875,540) |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | (14,928,960) | (19,533,683) |
| Translation adjustment | 185,175 | 615,859 |
| COMPREHENSIVE LOSS | (14,743,785) | (18,917,824) |
| LOSS PER SHARE, BASIC AND DILUTED | (1.660) | (2.256) |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | 8,991,766 | 8,659,718 |
BIOTRICITY, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.